FDC (531599) Stock Overview
Manufactures and trades in pharmaceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
531599 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
FDC Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹461.10 |
| 52 Week High | ₹569.15 |
| 52 Week Low | ₹358.95 |
| Beta | -0.061 |
| 1 Month Change | -0.63% |
| 3 Month Change | -5.75% |
| 1 Year Change | -11.22% |
| 3 Year Change | 63.71% |
| 5 Year Change | 31.48% |
| Change since IPO | 10,685.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531599 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.5% | 1.4% | 1.5% |
| 1Y | -11.2% | -7.2% | -4.7% |
Return vs Industry: 531599 underperformed the Indian Pharmaceuticals industry which returned -7.2% over the past year.
Return vs Market: 531599 underperformed the Indian Market which returned -6% over the past year.
Price Volatility
| 531599 volatility | |
|---|---|
| 531599 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: 531599 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 531599's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1936 | 6,857 | Nandan Chandavarkar | www.fdcindia.com |
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients.
FDC Limited Fundamentals Summary
| 531599 fundamental statistics | |
|---|---|
| Market cap | ₹75.07b |
| Earnings (TTM) | ₹2.69b |
| Revenue (TTM) | ₹21.18b |
Is 531599 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531599 income statement (TTM) | |
|---|---|
| Revenue | ₹21.18b |
| Cost of Revenue | ₹7.15b |
| Gross Profit | ₹14.04b |
| Other Expenses | ₹11.35b |
| Earnings | ₹2.69b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 16.53 |
| Gross Margin | 66.27% |
| Net Profit Margin | 12.70% |
| Debt/Equity Ratio | 0.9% |
How did 531599 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 03:04 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FDC Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Centrum Broking Limited |
| Kameswari V. S. Chavali | FirstCall Research |